trial

Evaluation of Single and Repeat Doses of GSK729327 in Healthy Volunteers

NCTId NCT00448890
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 79 (actual)
Sponsored by GlaxoSmithKline
Primary completion 2008-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
79 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Single
Start
2006-11
Primary completion
2008-12
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
GSK729327

Sponsors

GlaxoSmithKlineLead Sponsor

Sites

2 total
Berlin, GermanyLondon, United Kingdom

Facts & assertions

4 sourced
Enrollment
79
Phase
PHASE1
Primary Completion Date
2008-12
Status
COMPLETED
relationships
The graph out of here
drug
GSK729327
drug
lead_sponsor
GlaxoSmithKline
company
indication
Schizophrenia
indication
Schizophrenia
indication